Comparisons

Ozempic vs Zepbound: Main Differences Explained

GLP-1 Companion · 8 min read

Ozempic and Zepbound are two of the most widely prescribed injectable weight-management and diabetes medications in the United States. At first glance they appear similar: both are once-weekly subcutaneous injections that reduce appetite and blood sugar. But they contain entirely different molecules from different manufacturers, and their clinical profiles differ significantly. Understanding those differences helps patients and prescribers make informed treatment decisions.

The Fundamental Difference: Different Molecules

Ozempic contains semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. It selectively activates the GLP-1 receptor, which is involved in insulin secretion, appetite regulation, and gastric emptying. Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist manufactured by Eli Lilly. Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism is believed to explain tirzepatide's superior weight-loss results compared to GLP-1-only agents: GIP receptor activation in fat tissue and the brain appears to amplify the appetite-reducing effects of GLP-1 signaling.

FDA Approvals: Different Primary Indications

• Ozempic: FDA-approved December 2017 for type 2 diabetes management and cardiovascular risk reduction in adults with T2D and established cardiovascular disease
• Zepbound: FDA-approved November 2023 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
• Ozempic for weight loss: Ozempic is frequently prescribed off-label for weight management, but the FDA-approved semaglutide weight-loss product is Wegovy (2.4 mg), not Ozempic (max 2.0 mg)
• Zepbound for diabetes: Tirzepatide was first approved as Mounjaro for type 2 diabetes in May 2022; Zepbound is the same molecule at the same doses but in a different pen for a different indication

Weight Loss: A Significant Difference in Outcomes

The weight loss data comparing semaglutide and tirzepatide is among the most clinically significant findings in recent obesity medicine.

• Ozempic 1.0 mg (SUSTAIN-6 and SUSTAIN-8): Average weight loss of approximately 4 to 6 kg (~6% of body weight) over 40-56 weeks in patients with type 2 diabetes
• Ozempic 2.0 mg (SUSTAIN FORTE): Average weight loss of approximately 6.2 kg in T2D patients
• Zepbound 10 mg (SURMOUNT-1): Average weight loss of approximately 19.5% of body weight over 72 weeks
• Zepbound 15 mg (SURMOUNT-1): Average weight loss of approximately 20.9% of body weight over 72 weeks
• SURMOUNT-5 head-to-head (tirzepatide 15 mg vs semaglutide 2.4 mg/Wegovy): Tirzepatide produced -20.2% vs -13.7% weight loss

It is important to note that the Ozempic doses tested for weight loss are lower than Wegovy (max 2.0 mg vs 2.4 mg). Ozempic 1.0 mg produces approximately 6 kg of weight loss in diabetic populations, while Zepbound 15 mg produces approximately 22 kg of weight loss in patients with obesity. For a person weighing 250 pounds, this is the difference between losing roughly 13 pounds versus roughly 48 pounds over 72 weeks.

Side Effects: Similar Profile, Different Details

Both Ozempic and Zepbound produce GI-dominant side effects due to their effects on gastric motility and appetite signaling.

• Nausea: ~20% with Ozempic 1 mg vs 12-24% with Zepbound (dose-dependent)
• Diarrhea: ~8-9% with Ozempic vs 12-17% with Zepbound
• Vomiting: ~5-9% with Ozempic vs 5-9% with Zepbound
• Constipation: ~5% with Ozempic vs 11-17% with Zepbound
• Both medications carry a black-box warning for thyroid C-cell tumor risk
• Both increase the risk of pancreatitis and gallbladder disease

Despite tirzepatide's greater potency, the SURMOUNT-5 head-to-head trial found that tirzepatide had lower discontinuation rates due to adverse events (2.7% vs 5.6% for semaglutide 2.4 mg). The GIP receptor component of tirzepatide may modulate some of the GI effects associated with GLP-1 receptor activation.

Dosing and Administration

• Ozempic: 0.25 mg starter, escalate to 0.5 mg at week 5, 1.0 mg at week 9, optional 2.0 mg for additional glycemic control
• Zepbound: 2.5 mg starter, escalate by 2.5 mg every 4 weeks to a maximum of 15 mg
• Both are once-weekly subcutaneous injections into the abdomen, thigh, or upper arm
• Both use pre-filled pen devices and rotate injection sites with each dose
• Neither product pen is interchangeable with the other manufacturer's pens

Cost and Insurance Coverage

Cost and insurance coverage are among the most practically important differences for patients choosing between these medications.

• Ozempic list price: approximately $935 per month (all doses)
• Zepbound list price: approximately $1,060 per month (all doses)
• Ozempic insurance coverage: broadly covered by commercial insurance and most Medicare Part D plans because it is a diabetes drug
• Zepbound insurance coverage: significantly more variable; many commercial plans now cover it, but Medicare was restricted from covering obesity-only drugs under the Inflation Reduction Act rules until 2026 policy changes
• Ozempic manufacturer savings card: reduces out-of-pocket to approximately $25/month for commercially insured patients
• Zepbound manufacturer savings card: reduces out-of-pocket to approximately $25/month for eligible commercially insured patients
• No generics are available for either product as of April 2026

Who Is Ozempic For?

• Adults with type 2 diabetes seeking improved glycemic control
• Adults with T2D and established cardiovascular disease (CV event reduction indication)
• Patients with T2D who also have weight loss goals (produces meaningful weight loss as a secondary benefit)
• Patients whose insurance covers Ozempic but not weight-specific GLP-1 agents

Who Is Zepbound For?

• Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related health condition seeking maximum weight loss
• Patients who did not achieve sufficient weight loss on semaglutide-based products
• Patients with insulin resistance or prediabetes alongside obesity
• Patients whose primary goal is weight reduction and who have commercial insurance coverage

Off-Label Ozempic for Weight Loss: The Context

Millions of people have received Ozempic prescriptions off-label for weight management. From a clinical standpoint, this is understandable: Ozempic produces real weight loss, is broadly covered by insurance as a diabetes drug, and was available during periods when Wegovy experienced supply shortages. However, the maximum dose of Ozempic (2.0 mg) is lower than Wegovy (2.4 mg), and the pens are designed for different dose increments. For a patient with obesity but without diabetes, Wegovy is the appropriate on-label semaglutide formulation, and Zepbound is the appropriate on-label tirzepatide formulation.

The primary reason many patients end up on Ozempic for weight loss rather than Wegovy or Zepbound is insurance coverage. Ozempic, being a diabetes drug, is covered by far more plans. This is a formulary decision, not a clinical one.

The Bottom Line

Ozempic and Zepbound are distinct medications with different active ingredients, different FDA approvals, and significantly different weight-loss outcomes. Zepbound's tirzepatide produces roughly double the weight loss of Ozempic's semaglutide doses used in diabetes trials. For patients primarily seeking obesity treatment, Zepbound is clinically favored when insurance allows. For patients with type 2 diabetes, Ozempic remains a well-established, broadly covered first-line option with strong cardiovascular outcome data. The best choice depends on your diagnosis, insurance, and treatment goals.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.